Clinical Laboratory Improvement Advisory Committee (CLIAC), 5379 [2011-1999]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 20 / Monday, January 31, 2011 / Notices
Dated: January 24, 2011.
Carol E. Walker,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2011–2000 Filed 1–28–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
jlentini on DSKJ8SOYB1PROD with NOTICES
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Times and Dates:
9:15 a.m.–5 p.m., March 2, 2011
8:30 a.m.–12:30 p.m., March 3, 2011
Place: CDC, 1600 Clifton Road, NE.,
Tom Harkin Global Communications
Center, Building 19, Room 232,
Auditorium B, Atlanta, Georgia 30333.
Online Registration Required: In order
to expedite the security clearance
process at the CDC Roybal Campus
located on Clifton Road, all CLIAC
attendees are required to register for the
meeting online at least 14 days in
advance at https://wwwn.cdc.gov/cliac/
default.aspx by clicking the ‘‘Register for
a Meeting’’ link and completing all
forms according to the instructions
given. Please complete all the required
fields before submitting your
registration and submit no later than
February 16, 2011.
Status: Open to the public, limited
only by the space available. The meeting
room accommodates approximately 100
people.
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary,
Department of Health and Human
Services; the Assistant Secretary for
Health; the Director, CDC; the
Commissioner, Food and Drug
Administration (FDA); and the
Administrator, Centers for Medicare and
Medicaid Services (CMS), regarding the
need for, and the nature of, revisions to
the standards under which clinical
laboratories are regulated; the impact on
medical and laboratory practice of
proposed revisions to the standards; and
the modification of the standards to
accommodate technological advances.
Matters To Be Discussed: The agenda
will include agency updates from CDC,
CMS, and FDA; presentations and
discussions addressing activities of the
VerDate Mar<15>2010
16:38 Jan 28, 2011
Jkt 223001
Coordinating Council on the Clinical
Laboratory Workforce; the National
Institutes of Health Genetic Test
Registry design and responses from
testing laboratories; current testing
practices and oversight of cytogenetic
and cytogenomic testing; ongoing
studies evaluating laboratory practices;
and strategies for developing evidencebased methods for laboratory medicine
quality improvement.
Agenda items are subject to change as
priorities dictate.
Providing Oral or Written Comments:
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments
whenever possible.
Oral Comments: In general, each
individual or group requesting to make
an oral presentation will be limited to
a total time of five minutes (unless
otherwise indicated). Speakers must
also submit their comments in writing
for inclusion in the meeting’s Summary
Report. To assure adequate time is
scheduled for public comments,
individuals or groups planning to make
an oral presentation should, when
possible, notify the contact person
below at least one week prior to the
meeting date.
Written Comments: CLIAC accepts
written comments until the date of the
meeting (unless otherwise stated) for
individuals or groups unable to attend
the meeting. However, the comments
should be received at least one week
prior to the meeting date so that the
comments may be made available to the
Committee for their consideration and
public distribution. Written comments
and one hard copy with original
signature should be provided to the
contact person below. In addition,
written comments will be included in
the meeting’s Summary Report.
Contact Person for Additional
Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Science and
Standards, Laboratory Science, Policy
and Practice Program Office (LSPPPO),
Office of Surveillance, Epidemiology
and Laboratory Services, CDC, 1600
Clifton Road, NE., Mailstop F–11,
Atlanta, Georgia 30333; telephone (404)
498–2741; fax (404) 498–2219; or via email at Nancy.Anderson@cdc.hhs.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for the Centers
for Disease Control and Prevention and
the Agency for Toxic Substances and
Disease Registry.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
5379
Dated: January 25, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–1999 Filed 1–28–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Pregnancy
Risk Assessment Monitoring System
(PRAMS), DP11–001 Panels A, B, and
C, Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Times and Dates:
7:30 p.m.–9 p.m., March 1, 2011
(Closed)
8:30 a.m.–7 p.m., March 2, 2011
(Closed)
8:30 a.m.–5 p.m., March 3, 2011
(Closed)
Place: Georgian Terrace Hotel, 659
Peachtree Street, NE., Atlanta, GA
30308, Telephone: (404) 898–8305.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters To Be Discussed: The meeting
will include the initial review,
discussion, and evaluation of
‘‘Pregnancy Risk Assessment Monitoring
System (PRAMS), DP11–001 Panels A,
B, and C.’’
Contact Person for More Information:
Donald Blackman, Ph.D., Scientific
Review Officer, CDC, National Center
for Chronic Disease Prevention and
Health Promotion, Office of the Director,
Extramural Research Program Office,
4770 Buford Highway, NE., Mailstop K–
92, Atlanta, GA 30341, Telephone: (770)
488–3023, E-mail: DBY7@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
E:\FR\FM\31JAN1.SGM
31JAN1
]]>Agencies
[Federal Register Volume 76, Number 20 (Monday, January 31, 2011)]
[Notices]
[Page 5379]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-1999]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee (CLIAC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
committee:
Times and Dates:
9:15 a.m.-5 p.m., March 2, 2011
8:30 a.m.-12:30 p.m., March 3, 2011
Place: CDC, 1600 Clifton Road, NE., Tom Harkin Global
Communications Center, Building 19, Room 232, Auditorium B, Atlanta,
Georgia 30333.
Online Registration Required: In order to expedite the security
clearance process at the CDC Roybal Campus located on Clifton Road, all
CLIAC attendees are required to register for the meeting online at
least 14 days in advance at https://wwwn.cdc.gov/cliac/default.aspx by
clicking the ``Register for a Meeting'' link and completing all forms
according to the instructions given. Please complete all the required
fields before submitting your registration and submit no later than
February 16, 2011.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary, Department of Health
and Human Services; the Assistant Secretary for Health; the Director,
CDC; the Commissioner, Food and Drug Administration (FDA); and the
Administrator, Centers for Medicare and Medicaid Services (CMS),
regarding the need for, and the nature of, revisions to the standards
under which clinical laboratories are regulated; the impact on medical
and laboratory practice of proposed revisions to the standards; and the
modification of the standards to accommodate technological advances.
Matters To Be Discussed: The agenda will include agency updates
from CDC, CMS, and FDA; presentations and discussions addressing
activities of the Coordinating Council on the Clinical Laboratory
Workforce; the National Institutes of Health Genetic Test Registry
design and responses from testing laboratories; current testing
practices and oversight of cytogenetic and cytogenomic testing; ongoing
studies evaluating laboratory practices; and strategies for developing
evidence-based methods for laboratory medicine quality improvement.
Agenda items are subject to change as priorities dictate.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments whenever possible.
Oral Comments: In general, each individual or group requesting to
make an oral presentation will be limited to a total time of five
minutes (unless otherwise indicated). Speakers must also submit their
comments in writing for inclusion in the meeting's Summary Report. To
assure adequate time is scheduled for public comments, individuals or
groups planning to make an oral presentation should, when possible,
notify the contact person below at least one week prior to the meeting
date.
Written Comments: CLIAC accepts written comments until the date of
the meeting (unless otherwise stated) for individuals or groups unable
to attend the meeting. However, the comments should be received at
least one week prior to the meeting date so that the comments may be
made available to the Committee for their consideration and public
distribution. Written comments and one hard copy with original
signature should be provided to the contact person below. In addition,
written comments will be included in the meeting's Summary Report.
Contact Person for Additional Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch, Division of Laboratory Science
and Standards, Laboratory Science, Policy and Practice Program Office
(LSPPPO), Office of Surveillance, Epidemiology and Laboratory Services,
CDC, 1600 Clifton Road, NE., Mailstop F-11, Atlanta, Georgia 30333;
telephone (404) 498-2741; fax (404) 498-2219; or via e-mail at
Nancy.Anderson@cdc.hhs.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Dated: January 25, 2011.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2011-1999 Filed 1-28-11; 8:45 am]
BILLING CODE 4163-18-P
